Clinical studies on iron chelation in patients with thalassemia major.
作者信息
Freedman M H, Olivieri N, Benson L, Liu P, McClelland R, St Louis P, Templeton D, Koren G
机构信息
Hospital for Sick Children, Toronto General Hospital, University of Toronto, Canada.
出版信息
Haematologica. 1990 Sep-Oct;75 Suppl 5:74-83.
PMID:2086384
Abstract
摘要
相似文献
1
Clinical studies on iron chelation in patients with thalassemia major.重型地中海贫血患者铁螯合治疗的临床研究
Haematologica. 1990 Sep-Oct;75 Suppl 5:74-83.
2
Iron chelating therapy in thalassemia: current problems.地中海贫血的铁螯合疗法：当前问题
Haematologica. 1990 Sep-Oct;75 Suppl 5:84-8.
3
Iron metabolism and iron chelation in the thalassaemia disorders.
Haematologica. 1990 Sep-Oct;75 Suppl 5:66-71.
4
[Iron-chelating treatment].
Haematologica. 1989 Oct;74(5 Suppl):241-51.
5
The treatment of Cooley's anemia.
Haematologica. 1990 Sep-Oct;75 Suppl 5:57-65.
6
Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.去铁酮与去铁胺联合治疗对快速清除地中海贫血患者体内过量心脏铁及预防心脏病的有效性。国际口服螯合剂委员会方案。
Hemoglobin. 2006;30(2):239-49. doi: 10.1080/03630260600642567.
7
Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.地中海贫血中的铁螯合疗法：联合治疗还是单一疗法？埃及的经验。
Ann Hematol. 2008 Jul;87(7):545-50. doi: 10.1007/s00277-008-0471-2. Epub 2008 Mar 20.
8
Iron metabolism in thalassemia intermedia.中间型地中海贫血的铁代谢
Haematologica. 1990 Sep-Oct;75 Suppl 5:89-95.
9
Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.重型β地中海贫血患者从去铁胺治疗转换为去铁酮治疗后心肌功能障碍的消退
Hemoglobin. 2006;30(2):229-38. doi: 10.1080/03630260600642559.
10
Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.地中海贫血患者中去铁胺与地拉罗司联合治疗：对尿铁排泄的影响
Haematologica. 2003 Dec;88(12):1423-5.
Zotero 插件